This content is from: Premium These Biopharma Funds Made a Comeback Last Year While some funds posted huge losses in 2022, several others managed to turn sharp losses into profitability. By Stephen Taub January 19, 2023
This content is from: Premium Averill Launches a New Fund Averill Madison will have a long bias and will focus primarily on large-cap stocks. By Stephen Taub January 17, 2023
This content is from: Premium What Drove Third Point’s Disastrous Year Equities weren’t the only strategy that caused Dan Loeb’s hedge fund to post its worst results in 14 years. By Stephen Taub January 10, 2023
This content is from: Premium JW Asset Management Has a Sobering Year The firm’s big bet on cannabis paid off big in 2020 — but 2022 is a different story. By Stephen Taub December 19, 2022
This content is from: Premium Life Sciences Funds Post Mixed Results in September Several funds moved closer to breakeven, while others extended their already sharp losses. By Stephen Taub October 14, 2022
Sponsored Biodiversity: Why Investors Should Care It’s time for the finance industry to recognize that nature is the economy’s most vital asset. Sponsored by Pictet Asset Management December 06, 2022
